Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma 3Urogenital Neoplasms 2Prostatic Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Male Urogenital Diseases 2Genital Neoplasms, Male 2Lung Neoplasms 1Localized Prostate Cancer 1Genital Diseases, Male 1Genital Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × padeliporfin × Clear all
NCT00974662 2015-04-28

Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Steba Biotech S.A.

Phase 2 Terminated
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡